Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Gastrointestinal Cancer Gastrointestinal Cancer—Colorectal and Anal

Gastrointestinal Cancer—Colorectal and Anal

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
 
Thierry Andre, Kai-Keen Shiu, Tae Won Kim, et al.
 Clinical trial information: NCT02563002
 
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
 
Akihito Tsuji, Hisatsugu Ohori, Tatsuro Yamaguchi, et al.
 Clinical trial information: NCT02515734. Clinical trial information: UMIN000018217.
 
Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
 
Sebastian Stintzing, Kathrin Heinrich, David Tougeron, et al.
 Clinical trial information: NCT04034459
 
Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).
 
Dominik Paul Modest, Meinolf Karthaus, Stefan Frühauf, et al.
 Clinical trial information: NCT01991873
 
Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.
 
Richard Adams, David Fisher, Janet Graham,  et al.
Clinical trial information: ISRCTN#90061546.
 
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
 
Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav, et al.
Clinical trial information: NCT03384940
 
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.
 
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, et al.
Clinical trial information: 2016-002597-12.
 
The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
 
Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, et al.
Clinical trial information: jRCTs031180122.